

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

APR 3 1992

OFFICE OF **PESTICIDES AND TOXIC** SUBSTANCES

MEMORANDUM

Simazine Meeting with Ciba-Geigy. SUBJECT:

TO:

Venus Eagle, Review Manager

Special Review and Reregistration Division (H7508W)

FROM:

Steven M. Knott, Chemist

Special Review and Registration Section II

Steven M. Wrott Occupational and Residential Exposure Branch

Health Effects Division (H7509C)

THRU:

Mark Dow, Ph.D., Section Head atlan C. Sellosse h m D

Special Review and Registration Section II Occupational and Residential Exposure Branch

Health Effects Division (H7509C)

Charles L. Trichilo, Ph.D., Chief

Occupational and Residential Exposure Branch

Health Effects Division (H7509C)

Ciba-Geigy has requested a meeting (to be held April 7, 1992) with the Agency to discuss their "90-day" response to the September 12, 1991 Data Call In (DCI) for Simazine. Occupational and Residential Exposure Branch (OREB) has reviewed the "90-day" response and concluded that branch representation at the subject meeting is not warranted.

Ciba-Geigy's response to the DCI requirements that are relevant to occupational exposure is as follows:

Guideline #'s 231 and 232 - "Ciba Geigy has also participated in the development of a generic data base for exposure information. We wish to rely on this in lieu of generating additional exposure data on simazine."

OREB is always willing to review generic or surrogate data submitted to satisfy a particular data requirement. However, the registrant should be aware that if such a submission is rejected, the data requirement must still be satisfied by the deadline specified in the original DCI. Therefore, it would be prudent for the registrant to submit the surrogate data to the Agency as soon as possible. If the surrogate studies have already been submitted to the Agency, they should be referenced by MRID number in the registrant's exposure assessment or waiver request. If the surrogate studies are available in the published literature, complete copies of the published report and, if possible, the raw data collected during the study should be submitted to the Agency by the registrant.

cc: Correspondence File Circulation Simazine File